VALTYRON: Scientific Relevance

VALTYRON: Scientific Relevance

We and our academic partners spent ~ 20 years on scientific studies ranging from biochemical assays to clinical examinations to develop VALTYRON®.

VALTYRON® contains Valyl-Tyrosine with scientifically demonstrated activity to inhibit the production of angiotensin II which is responsible for the regulation of blood pressure.

Scientific studies showed that oral administration of VALTYRON® has the benefit to maintain normal blood pressure.

No side effect such as dry cough has been observed for > 20 years.

List of publications

1. Suetsuna K. et al. Nippon Suisan Gakkaishi, 54, 1853 (1988).
2. Matsui T. et al. Biosci. Biotech. Biochem. 57, 922-925 (1993).
3. Matsufuji H. et al. Biosci. Biotech. Biochem. 58, 2244-2245 (1994).
4. Matsufuji H. et al. Biosci. Biotech. Biochem. 59, 1398-1401 (1995).
5. Kawasaki T. et al. J. Human. Hypertens. 14, 519-523, (2000).
6. Kajimoto O. et al. J. Nutr. Food, 6, 65-82 (2003).
7. Matsui T. et al. Clin. Exp. Pharmacol. Phys. 29, 204-208 (2002). 
8. Osajima K.et al. Int. J. Toxicol. 28, 341-356 (2009).
9. Assunҫão-Miranda I. et al. Regul. Pept. 127, 151-157 (2005).
10. Axelband F. et al. Regul. Pept. 155, 81-90 (2009).
11. Axelband F. et al. Regul. Pept. 177, 27-34 (2012).
12. Dias J. et al. Am. J. Renal. Physiol. 306, F855-F863 (2014).
13. Erdmann K. et al. J. Nutr. 136, 2148-2162 (2008).
14. Kanagawa N. et al. FEBS Lett. 584, 599-604 (2010).
15. Agostoni CV. et al. EFSA Journal, 8(6), 1684 (2010).

• US Patent No. 6,905,704
• EFSA Panel, Scientific Opinion on the safety of ‘sardine Peptide Product’, (2010)
• GRAS: GRN000360 FDA 2011
• NDI Notification Report #845, 2014